The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
Open accessAbstract
Idiopathic hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL) comprise a spectrum of indolent to aggressive diseases characterized by unexplained, persistent hypereosinophilia. These disorders have eluded a unique molecular explanation, and therapy has primarily been oriented toward palliation of symptoms related to organ involvement. Recent reports indicate that HES and CEL are imatinib-responsive malignancies, with rapid and complete hematologic remissions observed at lower doses than used in chronic myelogenous leukemia (CML). These BCR-ABL–negative cases lack activating mutations or abnormal fusions involving other known target genes of imatinib, implicating a novel tyrosine kinase in their pathogenesis. A bedside-to-benchtop translational research effort led to the identification of a constitutively activated fusion tyrosine kinase on chromosome 4q12, derived from an interstitial deletion, that fuses the platelet-derived growth factor receptor-α gene (PDGFRA) to an uncharacterized human gene FIP1-like-1 (FIP1L1). However, not all HES and CEL patients respond to imatinib, suggesting disease heterogeneity. Furthermore, approximately 40% of responding patients lack the FIP1L1-PDGFRA fusion, suggesting genetic heterogeneity. This review examines the current state of knowledge of HES and CEL and the implications of the FIP1L1-PDGFRA discovery on their diagnosis, classification, and management. (Blood. 2004;103:2879-2891)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
Self-citationThe roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558
Self-citationThe hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.
Chusid, M. J., Dale, D. C., West, B. C., & Wolff, S. M. (1975) · PubMed · Cited by 1,233
Golub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Self-citationTHE HYPEREOSINOPHILIC SYNDROME: Analysis of Fourteen Cases With Review of The Literature
CHUSID, M. J., DALE, D. C., WEST, B. C., & WOLFF, S. M. (1975) · Medicine · doi:10.1097/00005792-197501000-00001 · Cited by 1,078
The idiopathic hypereosinophilic syndrome
Weller, P., & Bubley, G. (1994) · Blood · doi:10.1182/blood.v83.10.2759.2759 · Cited by 929
FAUCI, A. S., HARLEY, J. B., ROBERTS, W. C., FERRANS, V. J., GRALNICK, H. R., & BJORNSON, B. H. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-1-78 · Cited by 823
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Cited by
IgE, mast cells, basophils, and eosinophils
Stone, K. D., Prussin, C., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.017 · Cited by 1,680
Ammirati, E., Frigerio, M., Adler, E. D., Basso, C., Birnie, D. H., Brambatti, M., Friedrich, M. G., Klingel, K., Lehtonen, J., Moslehi, J. J., et al. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.120.007405 · Cited by 811
Roberts, K. G., Gu, Z., Payne-Turner, D., McCastlain, K., Harvey, R. C., Chen, I.-M., Pei, D., Iacobucci, I., Valentine, M., Pounds, S. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.0073 · Cited by 453
Diagnosis and Treatment of Acute Myocarditis: A Review
Ammirati, E., & Moslehi, J. J. (2023) · JAMA · doi:10.1001/jama.2023.3371 · Cited by 379
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
Self-citation
Metadata
- Authors
- Gotlib, J., Cools, J., Malone, J. M., Schrier, S. L., Gilliland, D. G., & Coutré, S. E.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-04-15
- Volume
- 103
- Issue
- 8
- Pages
- 2879-2891
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2003269232
- Cited by
- 290
- References
- 149
- FWCI
- 13.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. https://app.cochat.ai/papers/10.1182/blood-2003-06-1824
- The paper
- Gotlib, J., Cools, J., Malone, J. M., Schrier, S. L., Gilliland, D. G., & Coutré, S. E. (2004). The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. https://doi.org/10.1182/blood-2003-06-1824
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.